<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03646682</url>
  </required_header>
  <id_info>
    <org_study_id>CaffERM</org_study_id>
    <nct_id>NCT03646682</nct_id>
  </id_info>
  <brief_title>Pharmakokinetik of Caffeine in Epiretinal Membranes After Oral Intake: a Pilot Study</brief_title>
  <official_title>Pharmakokinetik of Caffeine in Epiretinal Membranes After Oral Intake: a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vienna Institute for Research in Ocular Surgery</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vienna Institute for Research in Ocular Surgery</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Caffeine concentrations in the vitreous Body and exzised epiretinal membranes are measured by
      gas-chromatography/mass spectrometry.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Caffeine concentrations in the vitreous Body and exzised epiretinal membranes are measured by
      gas-chromatography/mass spectrometry. One hour before surgery patients in the caffeine Group
      will receive 180mg of caffeine. in all patients vitrectomy with Membrane Peeling will be
      performed, due to epiretinal membranes
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 13, 2018</start_date>
  <completion_date type="Actual">December 1, 2019</completion_date>
  <primary_completion_date type="Actual">December 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>concentration of caffeine in vitreous probes and epiretinal membranes</measure>
    <time_frame>one hour</time_frame>
    <description>concentration of caffeine in the probes will be measuread by gas-chromatography/mass spectrometry</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Epiretinal Membrane</condition>
  <arm_group>
    <arm_group_label>caffeine group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>180mg of caffeine will be given orally one jour before vitrectomy with membrane peeling</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>no caffeine will be given before vitrectomy with membrane peeling, patients are drinking no coffee in general</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>vitrectomy with membrane peeling</intervention_name>
    <description>during vitrectomy with membrane peeling a prob of the vitreous body and the excised epiretinal membrane will be harvested for gas-chromatography/mass spectrometry</description>
    <arm_group_label>caffeine group</arm_group_label>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  epiretinale membrane

        Exclusion Criteria:

          -  none
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oliver Findl, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vienna Institute for Research in Ocular Surgery</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vienna Institute for Research in Ocular Surgery (VIROS), Hanusch Hospital Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1140</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>August 23, 2018</study_first_submitted>
  <study_first_submitted_qc>August 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 24, 2018</study_first_posted>
  <last_update_submitted>March 9, 2020</last_update_submitted>
  <last_update_submitted_qc>March 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vienna Institute for Research in Ocular Surgery</investigator_affiliation>
    <investigator_full_name>Prim. Prof. Dr. Oliver Findl, MBA</investigator_full_name>
    <investigator_title>Head of Department of Ophthalmology, Professor, MBA</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epiretinal Membrane</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

